buyModerate

Sands Capital Life Sciences Pulse Fund II, L.P. bought $3.0M of IKT

owner at Inhibikase Therapeutics, Inc.. 2,068,965 shares at an average of $1.45, traded Nov 21, 2025, filed Nov 24, 2025.

Conviction score

Value

$3.0M

2,068,965 shares

Holdings after

13,018,965

+19% from before

From 52-week low

+4%

low $1.43, close $1.49

From 52-week high

-62%

high $3.97, as of Nov 21, 2025

Score components

Role
10% owner
+12
Trade size
$3.0M at market
+25
Relative to holdings
Holdings up 19%
+3
Price context
4% above the 52-week low; 62% below the 52-week high
+18
Cluster
No other insider buying within 14 days
0
Repeat buying
First buy in 90 days
0
Track record
Too few past buys to judge (0 with prices)
0
Outside holder
A 10% owner who is not an officer or director
-5

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m +6.5%, 3m +16.1%, 6m +9.0%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

IKTOct 9, 2026 · close 1.97

Since filing Nov 24, 2025: +27.1%SPY +17.7% · excess +9.4%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001875620-25-000025, as filed. Open on EDGAR

Date	Transaction	Shares	Price	Value	Holdings after	Filed
Nov 21, 2025	POpen-market purchase Common Stock	+2,068,965	$1.45	$3.0M	13,018,965	Nov 24, 2025

Related signals

Other insiders at Inhibikase Therapeutics, Inc. and this insider’s other filings.

Score	Company	Insider	Value	Holdings	Filed
63Notable	IKTbuy 3 Inhibikase Therapeutics, Inc.	Roberto Bellini director	$2.0M 1,460,000 shares	-	Oct 23, 2024
56Moderate	IKTbuy 3 Inhibikase Therapeutics, Inc.	Amit Munshi director	$500k 365,000 shares	-	Oct 23, 2024
50Moderate	IKTbuy 3 Inhibikase Therapeutics, Inc.	Arvind Kush director	$199k 145,000 shares	-	Oct 23, 2024

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.